Matrubials Analysis: $2M Raised
What is Matrubials?
Matrubials develops milk-derived antibacterial therapeutics targeting infections, focusing on women's health issues like Bacterial Vaginosis.
Product Features & Capabilities
- Bacterial Vaginosis treatment, topical therapeutics, antibacterial therapeutics, anti-pathogenic molecules from milk, antimicrobial peptides from mammalian milk, AI-enabled technology for bioactive molecule identification.
How much Matrubials raised
Seed - $1.5 million
Approximately 39 months ago (around November 2021)Lead Investor: Not specified in the available sources.
Who are the founders of Matrubials
IS
Ishita Shah
CEO and co-founder
BG
Bruce German
Co-founder
CL
Carlito Lebrilla
Co-founder
DM
David Mills
Co-founder
Competitors Overview
Matrubials operates in the antibacterial therapeutics market, particularly focusing on women's health issues like Bacterial Vaginosis. Its main competitors include:
- Pfizer Inc. - A major player in the pharmaceutical industry, Pfizer offers a range of antibacterial treatments and has signific
Business Model
Focus on developing therapeutics; revenue from grants and partnerships in healthcare.
Investors
- Y Combinator
- Globivest
- Sunstone Management
- National Institutes of Health
- Gaingels
- Pitch Elk Grove
Market Focus
Matrubials primarily focuses on the healthcare industry, specifically developing novel antibacterial therapeutics derived from milk to address bacterial infections and antimicrobial resistance, with an initial emphasis on women's health issues such as Bacterial Vaginosis.
See something that needs updating? Suggest edits to this profile.